Reducing body myopathy - A new pathogenic FHL1 variant and literature review.
Mota IA, Correia CDC, Fontana PN, Carvalho AAS.
Neuromuscul Disord. 2021 Sep;31(9):847-853. doi: 10.1016/j.nmd.2021.03.013. Epub 2021 Apr 15.
FHL1-mutated reducing body myopathy.
Lim KY, Kim HH, Sung JJ, Oh BM, Kim K, Park SH.
Neuropathology. 2020 Apr;40(2):185-190. doi: 10.1111/neup.12619. Epub 2019 Dec 5.
Reducing body myopathy and other FHL1-related muscular disorders.
Schessl J, Feldkirchner S, Kubny C, Schoser B.
Semin Pediatr Neurol. 2011 Dec;18(4):257-63. doi: 10.1016/j.spen.2011.10.007.
Reducing body myopathy.
Brooke MH, Neville HE.
Neurology. 1972 Aug;22(8):829-40. doi: 10.1212/wnl.22.8.829.
Reducing body myopathy associated with the LIM2 p.(His123Arg) FHL1 variant.
Darki L, Jalali-Sohi A, Guzman S, Mathew AJ, Bucelli RC, Hurth KM, Beydoun SR.
Clin Neurol Neurosurg. 2021 Aug;207:106795. doi: 10.1016/j.clineuro.2021.106795. Epub 2021 Jul 7.
Inclusion body myositis: evolving concepts.
Perez-Rosendahl M, Mozaffar T.
Curr Opin Neurol. 2022 Oct 1;35(5):604-610. doi: 10.1097/WCO.0000000000001095.
Delayed onset muscle soreness : treatment strategies and performance factors.
Cheung K, Hume P, Maxwell L.
Sports Med. 2003;33(2):145-64. doi: 10.2165/00007256-200333020-00005.
Achilles Tendinopathy: Pathophysiology, Epidemiology, Diagnosis, Treatment, Prevention, and Screening.
Knapik JJ, Pope R.
J Spec Oper Med. 2020 Spring;20(1):125-140. doi: 10.55460/QXTX-A72P.
Current diagnosis and treatment of polymyositis and dermatomyositis.
Sasaki H, Kohsaka H.
Mod Rheumatol. 2018 Nov;28(6):913-921. doi: 10.1080/14397595.2018.1467257. Epub 2018 May 9.
Clinical and genetic characteristics of Chinese patients with reducing body myopathy.
Chen L, Lin HX, Yang XX, Chen DF, Dong HL, Yu H, Liu GL, Wu ZY.
Neuromuscul Disord. 2021 May;31(5):442-449. doi: 10.1016/j.nmd.2021.02.009. Epub 2021 Feb 12.
